Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) have earned an average recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $7.33.

Several research firms have issued reports on HTGM. Zacks Investment Research cut shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 15th. Cantor Fitzgerald set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Monday, April 8th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of HTG Molecular Diagnostics in a research note on Wednesday, December 19th. Finally, ValuEngine cut shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th.

NASDAQ HTGM traded down $0.07 on Monday, hitting $2.72. The stock had a trading volume of 240,500 shares, compared to its average volume of 347,774. HTG Molecular Diagnostics has a 52-week low of $2.03 and a 52-week high of $5.46. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.42 and a quick ratio of 5.23. The stock has a market capitalization of $79.82 million, a PE ratio of -4.53 and a beta of 1.84.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Thursday, March 7th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.13. HTG Molecular Diagnostics had a negative net margin of 76.52% and a negative return on equity of 64.49%. The business had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $7.87 million. On average, research analysts anticipate that HTG Molecular Diagnostics will post -0.59 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Kalos Management Inc. raised its position in shares of HTG Molecular Diagnostics by 6.5% during the 4th quarter. Kalos Management Inc. now owns 74,420 shares of the medical research company’s stock valued at $179,000 after buying an additional 4,520 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of HTG Molecular Diagnostics during the 3rd quarter valued at $1,089,000. Virtu Financial LLC purchased a new stake in shares of HTG Molecular Diagnostics during the 3rd quarter valued at $215,000. Stonepine Capital Management LLC raised its position in shares of HTG Molecular Diagnostics by 399.6% during the 4th quarter. Stonepine Capital Management LLC now owns 2,675,889 shares of the medical research company’s stock valued at $6,797,000 after buying an additional 2,140,299 shares in the last quarter. Finally, FMR LLC raised its position in shares of HTG Molecular Diagnostics by 2.9% during the 3rd quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock valued at $18,120,000 after buying an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 50.52% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Story: Catch-Up Contributions

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.